AGK Unleashes CD8+ T Cell Glycolysis to Combat Tumor Growth

Peipei Zhou; Hongbo Chi

doi:10.1016/j.cmet.2019.07.008

AGK Unleashes CD8⁺ T Cell Glycolysis to Combat Tumor Growth

Cell Metab. 2019 Aug 6;30(2):233-234. doi: 10.1016/j.cmet.2019.07.008.

Authors

Peipei Zhou¹, Hongbo Chi²

Affiliations

¹ Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
² Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: hongbo.chi@stjude.org.

PMID: 31390548
DOI: 10.1016/j.cmet.2019.07.008

Abstract

Elevated glycolytic metabolism is essential for CD8⁺ T cell antitumor function, but cell-intrinsic factors modulating this process remain elusive. In this issue, Hu et al. (2019) show that the lipid kinase acylglycerol kinase (AGK) promotes the glycolytic and functional fitness of CD8⁺ T cells by inactivating PTEN and boosting mTOR activity, thereby promoting antitumor activity.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

CD8-Positive T-Lymphocytes*
Glycolysis
Humans
Neoplasms*
Phosphotransferases (Alcohol Group Acceptor)

Substances

Phosphotransferases (Alcohol Group Acceptor)
acylglycerol kinase